87745-28-6 Usage
Uses
Used in Pharmaceutical Industry:
Bryostatin 2 is used as a pharmaceutical agent for its potential role in treating various diseases. Its activation of protein kinase C (PKC) makes it a candidate for research into conditions that may be influenced by PKC activity, such as cancer and neurodegenerative disorders.
Used in Cancer Research:
In cancer research, Bryostatin 2 is utilized as a tool to investigate the role of PKC in tumor growth and progression. Its ability to modulate PKC activity can provide insights into the development of targeted therapies for cancer treatment.
Used in Neurodegenerative Disease Research:
Bryostatin 2 is also used in the study of neurodegenerative diseases due to its effects on PKC, which is implicated in the regulation of neuronal function and survival. Research into its potential neuroprotective properties could lead to the development of treatments for conditions such as Alzheimer's disease.
Used in Drug Development:
In the field of drug development, Bryostatin 2 serves as a lead compound for the design and synthesis of new pharmaceuticals targeting PKC. Its unique mechanism of action can inspire the creation of novel therapeutic agents with improved efficacy and selectivity.
Overall, Bryostatin 2's diverse applications across various industries highlight its potential as a versatile and valuable compound in medical and scientific research.
Check Digit Verification of cas no
The CAS Registry Mumber 87745-28-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,7,7,4 and 5 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 87745-28:
(7*8)+(6*7)+(5*7)+(4*4)+(3*5)+(2*2)+(1*8)=176
176 % 10 = 6
So 87745-28-6 is a valid CAS Registry Number.
InChI:InChI=1/C45H66O16/c1-9-10-11-12-13-14-37(49)59-41-29(21-39(51)56-8)20-32-24-35(27(2)46)58-40(52)23-30(47)22-33-25-36(48)43(5,6)44(53,60-33)26-34-18-28(19-38(50)55-7)17-31(57-34)15-16-42(3,4)45(41,54)61-32/h11-16,19,21,27,30-36,41,46-48,53-54H,9-10,17-18,20,22-26H2,1-8H3/b12-11+,14-13+,16-15+,28-19-,29-21+/t27-,30-,31?,32?,33-,34+,35-,36+,41+,44+,45-/m1/s1
87745-28-6Relevant academic research and scientific papers
Pettit, G. R.,Kamano, Y.,Aoyagi, R.,Herald, C. L.,Doubek, D. L.,et al.
, p. 985 - 994 (1985)
An intensive investigation of the marine animal Amathia convoluta (Bryozoa phylum) for antineoplastic constituents has led to the isolation and structural determination of bryostatin 8 (2).A total of 100 kg of Amathia convoluta was required to obtain some 4.2 mg of bryostatin 8.Evaluation of bryostatin 8 against the murine P388 lymphocytic leukemia showed substantial inhibition of growth (PS, cell line ED50, 1.3 x 10-3, T/C 174 at 0.11 mg/kg).A major part of the very strong antineoplastic activity axhibited by fractions prepared from Amathia convoluta was accounted for by the isolation of bryostatin 4 (1a), 5 (1c) and 6 (1b).All three bryostatins were obtained in yields comparable to that of bryostatin 8 and appear derived from the closely related marine bryozoan Bugula neritina.The epiphytic-like relationship of Bugula neritina to Amathia convoluta is discussed.
